- Apr 18, 2026
- 2403219710
TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way. We share that with you as Cash Back. Everyone wins!
.png)
